Contact
searchSearch
HMP Global

News

Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Histotripsy
Histotripsy Adoption in Interventional Oncology Presents Opportunities and Challenges in the United Kingdom
06/03/2026
Laura Simson, MA
06/03/2026
Vascular Disease Management
Clinical Trials
Surrogate Endpoints Remain a Challenge in Interventional Oncology Trials
05/12/2026
Laura Simson, MA
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined...
05/12/2026
Vascular Disease Management
Novel Local Therapies
Pulsed Electric Field Ablation Plus SBRT Preserves Quality of Life in Lung Tumors
04/13/2026
Laura Simson, MA
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study...
04/13/2026
Vascular Disease Management
Post-Thrombotic Syndrome
Pivotal Study of Minimally Invasive Stent Therapy Shows Improved Quality of Life for Patients With Blood Clots
04/12/2026
NIH-sponsored C-TRACT Trial finds opportunity to treat often ignored DVT complication. TORONTO (April 13, 2026)—The results of a prominent, National Institutes of Health (NIH) sponsored study into the treatment of post-thrombotic syndrome...
NIH-sponsored C-TRACT Trial finds opportunity to treat often ignored DVT complication. TORONTO (April 13, 2026)—The results of a prominent, National Institutes of Health (NIH) sponsored study into the treatment of post-thrombotic syndrome...
NIH-sponsored C-TRACT Trial...
04/12/2026
Vascular Disease Management
MSK Embolization
CUC America Announces Strategic Collaborations with Dr. Yuji Okuno and Dr. Osman Ahmed to Advance MSK Embolization and Expand Access to Minimally Invasive Pain Treatment in the United States
04/10/2026
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
Global pioneer of embolotherapy...
04/10/2026
Vascular Disease Management
Portal Hypertension
BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
04/09/2026
CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company)...
CE Marking and ARCH clinical...
04/09/2026
Vascular Disease Management
AML TUMORS
Fluidx Medical Announces First Patient Treated with Novel Embolic Gel
04/01/2026
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to...
04/01/2026
Vascular Disease Management
Acute Pulmonary Embolism
HI-PEITHO Trial Demonstrates Boston Scientific EKOS™ Endovascular System Is Superior to Standard of Care for Treatment of Acute Pulmonary Embolism
04/01/2026
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings...
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings...
Global randomized trial...
04/01/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest
Thrombectomy for Stroke
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
07/07/2026
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc....
07/07/2026
Cath Lab Digest
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management
BTK Treatment for CLTI
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort
07/02/2026
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow...
07/02/2026
Vascular Disease Management
Reperfusion Catheters
Now in Europe: RED™ 72 SILVER LABEL
06/30/2026
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
The RED 72 SILVER LABEL...
06/30/2026
Vascular Disease Management
Abdominal Aortic Aneurysm
Data Presented on Two-Year Proximal Neck Dynamics From First-in-Human Study of Abdominal Aortic Aneurysm Treatment
06/26/2026
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 –...
06/26/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use